Akriti Jain, MD

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

Akriti Jain, MD, discusses unmet needs in patients with low- and high-risk myelodysplastic syndromes.

Akriti Jain, MD, discusses updated data from the phase 3 MEDALIST trial evaluating luspatercept for the treatment of anemic myelodysplastic syndromes.

Akriti Jain, MD, discusses the outcomes of the phase 3 COMMANDS trial in transfusion-dependent lower-risk myelodysplastic syndromes.